Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

Inclusion Criteria: * Both gender, the person aged 19 or older * Patients who are diagnosed with primary Hypercholesterolemia or Mixed Dyslipidemia * LDL- C ≤ 250 mg/dL and TG \< 500 mg/dL on fasting status Exclusion Criteria: * Patients with Myopathy, Rhabdomyolysis, Fibromyalgia, hereditary neuromuscular disorders or family history, or Creatine kinase(CK) ≥ 2 x Upper Limit of Normal(ULN) on Visit 1 * Patients with severe renal disorders, Estimated Flomerular Filtration Rate (eGFR) \< 30 mL/min/1.73m\^2 on Visit 1 * Patients with hepatic failure or active or chronic hepatobiliary diseases or aspartate transaminase (AST) or alanine aminotransferase (ALT) ≥ 2.0 x ULN on visit 1